Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients (male and non-pregnant, non-lactating females) who completed the core CACZ885A2204, CACZ885A2206, or CACZ885A2207 study without serious or severe drug-related adverse effects may enter the extension study upon signing informed consent
You may not be if
Patients for whom continued treatment in the extension is not considered appropriate by the treating physician.
Patients who were non-compliant or who demonstrated a major protocol violation in the core study.
Patients who did not complete / discontinued from the core study.
Patients with drug related serious adverse events or severe adverse events.
Clareo Health | Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
